Geode Capital Management LLC Grows Stake in Delcath Systems, Inc. (NASDAQ:DCTH)

Geode Capital Management LLC grew its holdings in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 3.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 251,895 shares of the company’s stock after purchasing an additional 7,298 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of Delcath Systems worth $2,275,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Polar Asset Management Partners Inc. purchased a new position in shares of Delcath Systems during the 3rd quarter worth $1,594,000. Shellback Capital LP bought a new position in shares of Delcath Systems during the 2nd quarter valued at approximately $1,353,000. Principal Financial Group Inc. purchased a new stake in Delcath Systems in the 3rd quarter worth approximately $808,000. Renaissance Technologies LLC bought a new stake in Delcath Systems during the 2nd quarter worth approximately $694,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Delcath Systems during the second quarter valued at approximately $370,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on DCTH shares. Stephens restated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group reiterated a “buy” rating and set a $21.00 price objective on shares of Delcath Systems in a research report on Friday, October 18th. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a report on Monday, November 11th. Finally, StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $21.50.

Delcath Systems Stock Down 2.8 %

Delcath Systems stock opened at $12.30 on Wednesday. The company’s 50-day moving average price is $11.17 and its 200-day moving average price is $9.69. The company has a market cap of $393.28 million, a PE ratio of -9.11 and a beta of 0.87. Delcath Systems, Inc. has a twelve month low of $3.70 and a twelve month high of $13.30.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.